Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

NCT00679289 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Cutaneous Melanoma

Interventions

DRUG: HDI
DRUG: KW2871
DRUG: KW2871
DRUG: KW2871

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]